Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 491-495

  Trojanowski, John Q ^a   Hampel, Harald ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Clinical testing; Disease progression; Magnetic resonance imaging; Neurodegenerative disease diagnosis; Neuroimaging; Neuronal network dysfunction; Plasma

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID ANALYSIS; DEGENERATIVE DISEASE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; NOTE; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; SHY DRAGER SYNDROME;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 82755197883     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.07.004     Document Type: Note

References (32)

1. Aisen P.S., Petersen R.C., Donohue M., Gamst A., Raman R., Thomas R.G., Walter S., Trojanowski J.Q., Shaw L., Beckett L.A., Jack C.R., Jagust W., Toga A., Saykin A.J., Morris J.C., Green R.C., Weiner M.W. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010, 6:239-246. The Alzheimer's Disease Neuroimaging Initiative.
2. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. Nat. Rev. Neurol. 2010, 6:131-144.
3. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 1997, 88:1337-1342.
4. Buerger K., Frisoni G., Uspenskaya O., Ewers M., Zetterberg H., Geroldi C., Binetti G., Johannsen P., Rossini P.M., Wahlund L.O., Vellas B., Blennow K., Hampel H. Validation of Alzheimer's disease CSF and plasma biological markers - the multi-center reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp. Gerontol. 2009, 44:579-585.
5. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
6. Ewers, M., Sperling, R.A., Klunk, W.E., Weiner, M.W., Hampel, H., 2011. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci., in press.
7. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
8. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9:560-574.
9. Hampel H., Wilcock G., Andrieu S., Aisen P., Blennow K., Broich K., Carrillo M., Fox N.C., Frisoni G.B., Isaac M., Lovestone S., Nordberg A., Prvulovic D., Sampaio C., Scheltens P., Weiner M., Winblad B., Coley N., Vellas B. For the Oxford Task Force Group. 2010b. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 2011, 95:579-593.
10. Hampel H., Prvulovic D., Teipel S.J., Bokde A.L. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Prog. Neurobiol. 2011, 95:570-578.
11. Hebert L.E., Beckett L.A., Scherr P.A., Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 2001, 15:169-173.
12. Hedden T., Van Dijk K.R., Becker J.A., Mehta A., Sperling R.A., Johnson K.A., Buckner R.L. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 2009, 29:12686-12694.
13. Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J., Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
14. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Petersen R.C., Trojanowski J.Q. Modeling dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
15. Khachaturian Z.S., Snyder P.J., Doody R., Aisen P., Comer M., Dwyer J., Frank R.A., Holzapfel A., Khachaturian A.S., Korczyn A.D., Phelps C., Roses A., Simpkins J.W., Schneider L.S., Albert M.S., Egge R., Deves A., Ferris S., Greenberg B.D., Johnson C., Kukull W.A., Poirier J., Schenk D., Thies W., Gauthier S., Gilman S., Bernick C., Cummings J.L., Fillit H., Grundman M., Kaye J., Mucke L., Reisberg B., Sano M., Pickeral O., Petersen R.C., Mohs R.C., Buckholtz N., Carrillo M., Corey-Bloom J.P., Foster N.L., Jacobsen S., Lee V.M.-Y., Potter W.Z., Sabbagh M.N., Salmon D., Trojanowski J.Q., Wexler N. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009, 5:85-92.
16. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., McDonald W.C., Braak H., Petersen R.C. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 2003, 62:1087-1095.
17. Manton K.G. Recent declines in chronic disability in the elderly U.S. population: risk factors and future dynamics. Annu. Rev. Public Health 2008, 29:91-113.
18. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
19. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., Burke J.R., Hurd M.D., Potter G.G., Rodgers W.L., Steffens D.C., Willis R.J., Wallace R.B. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
20. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
21. Prvulovic D., Bokde A., Faltraco F., Hampel H. Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. Prog. Neurobiol. 2011, 95:557-569.
22. Savva G.M., Wharton S.G., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med. 2009, 360:2302-2309.
23. Sheline Y.I., Morris J.C., Snyder A.Z., Price J.L., Yan Z., D'Angelo G., Liu C., Dixit S., Benzinger T., Fagan A., Goate A., Mintun M.A. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J. Neurosci. 2010, 30:17035-17040.
24. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
25. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Figurski M., Coart E., Blennow K., Soares H., Simon A.J., Lewczuk P., Dean R.A., Siemers E., Potter W.Z., Lee V.M.-Y., Trojanowski J.Q. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011, The Alzheimer's Disease Neuroimaging Initiative, 2011.
26. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
27. The Alzheimer's Study Group Report, 2008. A National Alzheimer's Strategic Plan: The Report of the Alzheimer's Study Group. Available from: http://www.alz.org/news_and_events_16243.asp.
28. Trojanowski J.Q., Arnold S.E., Karlawish J.H., Brunden K., Cary M., Davatzikos C., Detre J., Gaulton G., Grossman M., Hurtig H., Jedrziewski K., McCluskey L., Naylor M., Polsky D., Schellenberg G.D., Siderowf A., Shaw L.M., Van Deerlin V., Wang L.-S., Werner R., Xie S.X., Lee V.M.-Y. Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimers Dement. 2010, 6:150-155.
29. Trojanowski J.Q., Vanderstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers S., Potter W.Z., Weiner M.W., Jack C.R., Jagust W., Toga A.W., Lee V.M.-Y., Shaw L.M. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2010, 6:230-238. The Alzheimer's Disease Neuroimaging Initiative.
30. Weiner M.W., Aisen P.S., Jack C.R., Jagust W.J., Trojanowski J.Q., Shaw L.M., Saykin A.J., Morris J.C., Cairns N., Beckett L.A., Toga A., Green R.C., Walter S., Soares H., Snyder P., Siemers E., Potter W., Cole P.E., Schmidt M. Progress report and future plans. Alzheimers Dement. 2010, 6:202-211. The Alzheimer's Disease Neuroimaging Initiative.
31. White L., Small B.J., Petrovitch H., Ross G.W., Masaki K., Abbott R.D., Hardman J., Davis D., Nelson J., Markesbery W. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J. Geriatr. Psychiatr. Neurol. 2005, 18:224-227.
32. Wimo, A., Prince, M., 2010. Alzheimer's Disease International World Alzheimer Report 2010 The Global Economic Impact of Dementia. Alzheimer's Disease International. http://www.alz.org/documents/national/World_Alzheimer_Report_2010.pdf.